Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
- Status
- COMPLETED
- Phase
- PHASE3
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
- Status
- COMPLETED
- Phase
- PHASE3
MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
- Status
- COMPLETED
- Phase
- PHASE3
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE4
Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- TERMINATED
- Phase
- PHASE2
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE4
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
- Status
- UNKNOWN
- Phase
- PHASE2